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Objective: To investigate the pharmaceutical equivalence of ten brands of ibuprofen
tablets (400 mg) purchased from pharmacies in Benin City, Nigeria.
Methods: The drug samples were subjected to uniformity of weight, crushing strength,
friability, melting point, disintegration and dissolution tests following acceptable and
ofﬁcial protocols. The ibuprofen content was determined using UV and high performance
liquid chromatography method.
Results: Crushing strength values of the drug samples ranged between 6 and 16 kp while
the disintegration times were between 7.43 and 10.40 min (for uncoated tablets) and
3.25–37.32 min (for coated tablets). Friability values were less than 1% and the melting
points of recrystallized ibuprofen from the samples ranged from 73.5 to 76.0 C. The
amount of ibuprofen released within 1 h ranged between 18% and 102% and two brands
failed the content of active ingredient in the UV method of assay while all the brands
passed the test using HPLC.
Conclusions: Ibuprofen (400 mg) tablets marketed in Benin City, Nigeria vary in
pharmaceutical quality.1. Introduction
Ibuprofen is formulated as tablets, caplets or capsules in
200 mg and 400 mg strengths. It is a nonsteroidal anti-
inﬂammatory drug with a half-life of 1.8–2 h. It is one of the
safest drugs employed for treatment of inﬂammation, pain and
fever [1,2]. Its oral dose is 200–400 mg (5–10 mg/kg in children),
every 4–6 h to a maximum of 1.2 g per day in adults. Although it
is not the most potent of the nonsteroidal anti-inﬂammatory
drugs, it represents a good balance of efﬁcacy and safety over
a wide dosage range when compared with others in the group
and it is also readily available and cost-effective.
Ibuprofen has analgesic and anti-inﬂammatory properties. It
is used in mild-to-moderate pain such as dysmenorrhea, head-
aches (including migraine), dental pain, postoperative pain and
musculoskeletal/joint disorders including osteoarthritis, rheu-
matoid arthritis and ankylosing spondylitis [3,4]. Reports havebeen made from various regions and quarters across the
country on the variations on the physicochemical and
pharmaceutical equivalence of the various brands of ibuprofen
tablets available in the Nigerian market [5,6].
Daily, health care givers are confronted with the problem of
generic substitution, inﬂuenced by factors such as cost, efﬁcacy,
esthetic packaging and recently the assignment of National
Agency of Food and Drug Control and Administration (NAF-
DAC) number on packaging [7]. Thus, the community pharmacist
faces the problem of making the right choice of selecting the most
effective brand to dispense to the patient. Therefore, it is
necessary to routinely assess the pharmaceutical quality of
drugs in Nigerian market [8]. Another salient aspect is in the
instrumentation for content analysis which may be inﬂuenced
by changes in environmental conditions. Hence it is necessary
to compare UV and high performance liquid chromatography
(HPLC) assay methods.
This work aims to establish if pharmaceutical equivalence
exists among the various brands of ibuprofen tablets (400 mg) in
the Nigeria market using Benin City as a reference point. Benin
City is a large metropolitan city located in the south–south
geopolitical zone of Nigeria. It has a projected population of
about 1.2 million [9]. The city has about 120 registeredan open access article under the CC BY-NC-ND
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the vicinity of the government hospitals (city centre), while
the remaining ones are scattered over the rest of the city [10].
2. Materials and methods
2.1. Sampling
The samples (Table 1) studied were purchased from phar-
macies across the city centre. Brands available in each pharmacy
were selected to make up the ten brands studied. A brand already
selected from one pharmacy was no longer considered in any
other one. Pure ibuprofen powder was gratefully received as a
gift sample from Edo Pharmaceuticals Nigeria Limited, Benin
City, Nigeria. All other reagents were of analytical grade and
water was double distilled.
2.2. Uniformity of weight
Twenty tablets were randomly selected from each brand and
weighed individually using the electronic weighing balance
(College B154, Mettler Toledo, Switzerland). The weight
(mean ± SD) was calculated.
2.3. Hardness test
The crushing strength was determined by diametric
compression of each of ten tablets per sample using a motorized
hardness tester (Campbell Electronics, Model HT-30/50, India).
The mean ± SD were calculated.
2.4. Friability test
The weight of ten tablets per sample was determined on the
electronic balance. The tablets were then placed in the drum of a
friabilator (Erweka GmbH, Germany) revolving at 25 r/min which
exposed the tablets to rolling and repeated shock resulting from
free fall within the apparatus. After 4min, the tablets were removed
from the friabilator and dusted and reweighed. Theweight losswas
obtained from the differences between the initial weight and ﬁnal
weight. The friability was calculated as the percentage weight loss.
2.5. Melting point
A tablet randomly selected from each brand was used for the
determination. The ibuprofen tablet was crushed to powderTable 1
Brands of ibuprofen tablets used in the study.
Code Brand name Country
of origin
Expiry
date
Batch
No.
NAFDAC
No.
A Ibudex-400 Nigeria 05-16 05006-1 04-4186
B Tabalon-400 Nigeria 08-18 R-1003 04-2215
C Buprol-400 Malaysia 03-15 N-3327 A4-1363
D Genafen-400 India 10-16 G-1177 04-5705
E Ibupkris-400 India 02-17 I-1813 A4-5656
F Ebu-400 Nigeria 01-17 D1159 A4-1204
G Espen-400 India 01-16 E-1127 04-3544
H Inbu-400 Nigeria 08-16 I-1523 04-2569
I Ibulab-400 India 09-16 13210 04-6315
J Brustan-N India 07-16 25/24/83 04-0694using a mortar and pestle. The powder was added in 200 mL of
n-hexane. The mixture was heated for 10 min with continuous
stirring. The cooled mixture was ﬁltered through a Whattman
ﬁlter paper (No.1) and the ﬁltrate evaporated to dryness in a hot
water bath to give ibuprofen crystals.
The crystals were packed into a capillary tube and tapped on
a hard surface to form a column at the bottom of the capillary
tube. The tube was inserted into a heating block of a Gallenkamp
melting point apparatus and already maintained at a temperature
of 70 C. The temperature of the heating block was raised at
0.5 C per min until the sample melts. The melting temperature
was recorded as the melting point. Triple determinations were
carried out in per brand.
2.6. Disintegration time
The disintegration times of six tablets per brand were deter-
mined in distilled water at (37.0 ± 0.5) C using the British
Pharmacopoeia (BP) disintegration tester (Mk IV, Manesty
Machines, UK). The apparatus is an assembly of tubes covered
at the lower end with a No. 10 mesh of 2 mm diameter and
opened at the upper end. The whole assembly of tubes is then
immersed inside a 1 L beaker containing 900 mL of distilled
water. The beaker was placed inside the water bath and main-
tained at a constant temperature of (37.0 ± 0.5) C. The tubes
were made to oscillate at a constant rate, that at the upward
stroke about 2.5 mL of the tubes were immersed in the medium
and at the downward stroke, the tube went deep inside the
medium leaving about 2.5 mL portion of the tube. The time
taken for all the 6 tablets to break up into granules that were able
to pass through the mesh was noted as the disintegration time.
The test was repeated to obtain the average disintegration time.
The SD were calculated.
2.7. Dissolution rate
Dissolution test was carried out on the tablets using the
United States Pharmacopeia (USP) dissolution apparatus II
(paddle method) (Dissolution Tester DIS 6000, Copley Scien-
tiﬁc, UK). A dissolution medium of 900 mL of phosphate buffer
pH 7.2 maintained at (37.0 ± 0.5) C with a basket revolution of
50 r/min was used. A 5 mL aliquots was withdrawn at various
intervals and replaced with an equivalent volume maintained at
same temperature (37.0 ± 0.5) C of the dissolution medium.
The samples were diluted with an equal volume of phosphate
buffer. This was continued for 60 min. The absorbances of the
resulting solutions were measured spectrophotometrically at
lmax of 221 nm (CE 7500, Cecil Instruments Ltd). The con-
centration and the percentage of drug released at each time in-
terval was determined using the equation from the standard
calibration plot obtained from the pure ibuprofen. A minimum of
triplicate determinations were carried out for each brand and the
results were reported as mean ± SD.
2.8. Content of active UV assay
2.8.1. Standard preparation
A total of 10 mg/mL standard solution was prepared by dis-
solving 100 mg of ibuprofen powder in a 100 mL volumetric
ﬂask with 0.1 mol/L NaOH solution and making up to volume.
A 1 mL aliquot of the solution was further diluted to 100 mL to
Figure 1. Chromatograms of brands A–J ibuprofen.
Sylvester Okhuelegbe Eraga et al./Asian Pac J Trop Biomed 2015; 5(10): 880–884882give the desired concentration. The absorbance of the resulting
solution was read at 221 nm.
2.8.2. Sample preparation
The average tablet weight of 20 tablets from each brand was
gotten. The tablets were crushed into powders using a tablet
miller (IKA tablet miller). Powder quantity equivalent to
100 mg ibuprofen was dissolved in a 100 mL volumetric ﬂask
with 0.1 mol/L NaOH solution and made up to volume. The
solution was ﬁltered with a Whattman ﬁlter paper (No. 1) and
1 mL aliquot of the solution was further diluted to 100 mL to
give a 10 mg/mL solution. The absorbance of the resulting so-
lution was read at 221 nm and the percentage content was
calculated.
2.9. HPLC assay
The HPLC system (Agilent Inﬁnity 1260, Agilent Technolo-
gies Inc., USA) has four gradient pumps incorporated with a
solvent degasser, injector, column oven and a diode array detector.
An Agilent ZORBAX Eclipse Plus C18 100 mm × 4.6 mm,
3.5 mm column was used as the stationary phase.
2.9.1. Standard preparation
Pure ibuprofen powder (160 mg) was weighed into a 100 mL
volumetric ﬂask containing about 70 mL of HPLC grade
methanol and sonicated for 20 min. The resultant solution was
allowed to settle and made up to volume. A 5 mL aliquot of the
solution was diluted to 100 mL to get a concentration of 80 mg/
mL. The standard solution was run on the HPLC. Six injections
were run for the standard to determine the system suitability and
were calibrated to see the correlations and relative standard
deviation [11].
2.9.2. Sample preparation
Twenty tablets randomly selected from each brand were
weighed and pulverized. The weight of powder equivalent to
400 mg ibuprofen was transferred into a 100 mL volumetric
ﬂask. About 70 mL of methanol was added and sonicated for
20 min. After dissolving, the solution was allowed to settle down
and made up to volume. The solution was ﬁltered through a
0.45 mm Sartorius nylon ﬁlter and 1 mL was taken and diluted to
50 mL with methanol in a volumetric ﬂask to get a test solution
of 80 mg/mL. The sample was analysed using HPLC. Two in-
jections were run on each brand and the area of the ibuprofen
peaks were quantiﬁed with the area of the peak of the ibuprofen
standard to get the amount of the ibuprofen in percentage present
in each brand. The mobile phase was also run with the test
samples to serve as the blank [11]. Agilent ChemStation software
was used to integrate and analyze HPLC peak responses for
quantitation of the peaks by area percent. Chromatograms
were shown in Figure 1.
3. Results
All the ibuprofen tablets investigated were all within their
shelf lives and were immediate released dosage forms with label
strength of 400 mg (Table 1). Brands A and B were uncoated
tablets while the others were coated. Of the ten brands studied,
ﬁve were formulated in India, four in Nigeria and one in
Malaysia and they were all registered with the NAFDAC.Table 2 shows some physicochemical parameters of the
various brands of ibuprofen tablets. The weight uniformity test
on the tablets indicated no signiﬁcant differences (P > 0.5) in the
weights of tablets from the different brands, hence conformed to
the BP speciﬁcation, i.e. that not more than two of the individual
weights should deviate from the average weight by more than
±5% and none should deviate by more than ±10% [12]. Despite
the uniformity of weights within each brand, there were
signiﬁcant weight variations among the brands. Table 2 also
shows that the mean tablet crushing strength for the samples
ranged from 6.14 to 15.93 kp. Although friability is a non-
ofﬁcial test, it is related to the hardness of the tablet and it is
the tendency of tablets to powder, chip, or fragment. It can
negatively affect the elegance, appearance and consumer
acceptance of the tablet. All the samples showed friability values
below 1%. The disintegration times of the samples did not meet
the BP 2009 requirements of within 15 min for uncoated tablets
and 60 min for coated tablets [12]. Tablets of brand C, F, G and I
which are uncoated did not meet the speciﬁcations. The in vitro
drug release data showed that all the samples did not released up
to 80% of their labeled contents within 1 h. The USP stated that
not less than 80% of the labeled amount of ibuprofen should be
released within 1 h [13]. Brands D, E, G, I and J did not comply
to this compendial requirement. The melting points of ibuprofen
extracted from all the brands ranged from 73.5 to 76 C. The BP
speciﬁes ranged between 75 and 78 C. Two brands (B and G)
did not meet this speciﬁcation [14].
The results of the assay of chemical content using UV and
HPLC analysis to determine the amount of ibuprofen present in
Table 2
Some physicochemical properties of ibuprofen tablets.
Brand
code
Weight (mg) Crushing
strength (kp)
Friability (%) Disintegration
time (min)
Amount released
at 60 min (%)
Melting
point (C)
A 532.00 ± 0.10 10.48 ± 0.76 0.19 ± 0.22 7.43 ± 0.05 87.20 ± 0.30 75.50 ± 0.32
B 625.00 ± 0.40 12.21 ± 0.59 0.32 ± 0.16 10.40 ± 0.23 90.20 ± 0.50 73.50 ± 0.60
C 661.00 ± 0.38 15.93 ± 0.50 0.30 ± 0.06 25.73 ± 0.40 83.50 ± 0.23 75.00 ± 0.34
D 759.00 ± 0.35 8.26 ± 0.64 0.13 ± 0.02 5.60 ± 0.04 78.00 ± 0.50 75.50 ± 0.16
E 722.00 ± 0.55 13.52 ± 0.125 0.12 ± 0.42 8.88 ± 0.32 63.40 ± 0.60 75.00 ± 0.32
F 714.00 ± 0.09 7.55 ± 1.12 0.14 ± 0.56 37.32 ± 1.18 99.40 ± 0.32 75.00 ± 0.87
G 900.00 ± 0.84 6.14 ± 1.43 0.22 ± 0.62 29.59 ± 0.53 37.20 ± 0.40 72.50 ± 0.45
H 838.00 ± 0.88 7.64 ± 0.64 0.35 ± 0.40 5.02 ± 0.06 101.50 ± 0.52 75.50 ± 0.12
I 861.00 ± 0.22 7.47 ± 0.41 0.22 ± 0.32 33.04 ± 1.12 18.80 ± 0.20 76.00 ± 0.32
J 1 017.00 ± 0.15 14.13 ± 0.48 0.10 ± 0.12 3.25 ± 0.13 39.60 ± 0.45 75.50 ± 0.40
Table 3
Assay result of the amount of ibuprofen obtained from UV and HPLC
analysis.
Brand code Amount (mg/tablet) Label claim (%)
Labeled UV HPLC UV HPLC
A 400 398.44 403.16 99.61 100.79
B 400 392.00 414.60 98.00 103.65
C 400 369.72 402.16 92.43 100.54
D 400 364.72 386.64 91.18 96.66
E 400 392.96 384.24 98.24 96.06
F 400 403.68 398.04 100.92 99.51
G 400 386.52 407.12 96.63 101.78
H 400 402.80 380.68 100.70 95.17
I 400 404.80 386.52 101.20 96.63
J 400 406.24 403.40 101.56 100.85
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105% of active drug content [12]. While brands C and D failed
this requirement in the UV assay, all the brands did meet this
speciﬁcation in the HPLC assay method.
4. Discussion
The physicochemical and pharmaceutical equivalence of ten
brands of ibuprofen tablets (400 mg) obtained from various
pharmacies across Benin City has been evaluated. All the brands
met compendial requirements with regards to uniformity of
weight, crushing strength and friability.
The pharmacopeia compliance with regard to uniformity of
weight of each brand studied is important since the uniformity of
dosage unit can be demonstrated by either weight variation or
content uniformity study [13]. These either reﬂect indirectly or
measure directly the amount of drug substance in the tablet [15].
Although there was compliance with each brand, the differ-
ences in tablet weight (a reﬂection of their sizes), among the
brands may have some negative psychological effects on clini-
cians and their patients since they could raise some doubts on the
general equivalence of the different brands of ibuprofen tablets
(400 mg) available. The World Health Organization model
formulary advises that a patient should be placed on a particular
brand, probably due to pharmacokinetic and psychological rea-
sons [16]. In Nigeria where the availability of a particular brand
for the patient concerned is never guaranteed at all times, it
would be advisable that manufacturers of this product
formulate equivalent sizes of tablets in order to assuagepatients’ worry regarding the identity and efﬁcacy of the
different brands because of the wide differences in tablet sizes.
Sufﬁcient tablet hardness is essential to ensure damage
resistance during handling, packaging and transportation.
Although BP recommends a crushing strength of 5–8 kp, an
overly hard tablet would lower disintegration time signiﬁcantly
and in turn dissolution [12]. The minimal friability values for all
the tablet brands is an indication of the ability of the tablet to
withstand stress due to abrasive forces, without crumbling
during transportation, packaging, handling and dispensing.
These values also reﬂect the hardness of the tablets.
Disintegration time is the rate determining step in drug ab-
sorption. The type and amount of excipients used by different
manufacturers may inﬂuence disintegration and consequently
the bioavailability of the drug. The disintegration times of the
different brands could not be predicted from their tablet crushing
strength values as brands C, F, G and I that failed the test and
had satisfactory crushing strength values. The high crushing
strength value of brand C could be responsible for its disinte-
gration time.
Based on the USP speciﬁcations, brands A, B, C, F and H
released over 80% of their drug content within 1 h while D, E,
G, I and J released variable amounts of their active content [13].
Here, their disintegration time did not have a direct relationship
with their drug release. Brands D, E and J had disintegration
time below 10 min, hence a drug release above 80% would
have been expected. This could be due to improper
formulation technique leading to disintegration into coarse
particles and preventing the drug from going into solution.
The amount of drug released by brands G and I could be a
direct consequence of their disintegration times that was
greater than or equal to 30 min. Although brand F had a
disintegration time of 37 min, its drug release still reached
99% in 1 h.
The chemical content assay using the UV spectroscopic
method showed that brands C and D failed to meet the com-
pendial requirements while the all the brands passed HPLC
method. The chromatographic method is more sensitive and
reliable assay. The HPLC technique is usually used to further
support the results by the UV and it showed that all brands
passed the assay test.
It can therefore be concluded that ibuprofen tablets marketed in
Benin City vary in their physicochemical qualities, though they
may be chemically equivalent. Since there was much variation in
their physicochemical properties, it is an indication that bioavail-
ability will differ to a large extent. Thus, in clinical practice, brand
Sylvester Okhuelegbe Eraga et al./Asian Pac J Trop Biomed 2015; 5(10): 880–884884substitution should not be encouraged as therapeutic outcome
expected would not be achieved at the expected time.
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